MMW FM-CW ground-based SAR

This paper presents the design of two ground based synthetic aperture radar (GB-SAR) systems working at 94 and 300 GHz respectively. Frequency-modulated continuous-wave (FM-CW) technique is used for both systems, being described in the first section. Afterwards the first design at 94GHz is presented, explaining its geometry of exploration and describing the architecture of the W-band radar setup. Regarding the integrated receiver system, two models of low noise (LNA) and medium power amplifiers are disclosed, presenting noise figure and S parameters curves comprising frequencies between 75 and 110 GHz (W-band). Finally the second radar setup working at 300GHz is presented, depicting the hardware block diagram and explaining the main performance parameters of the system

Desarrollo y aplicaciones de radares de alta resolución en bandas milimétricas

Las bandas de las denominadas ondas milimétricas y submilimétricas están situadas en la región del espectro entre las microondas y el infrarrojo. La banda de milimétricas se sitúa entre 30 y 300 GHz, considerada normalmente como la banda EHF (Extremely High Frequency). El margen de frecuencias entre 300 y 3000 GHz es conocido como la banda de ondas submilimétricas o de terahercios (THz). Sin embargo, no toda la comunidad científica está de acuerdo acerca de las frecuencias que limitan la banda de THz. De hecho, 100 GHz y 10 THz son considerados comúnmente como los límites inferior y superior de dicha banda, respectivamente. Hasta hace relativamente pocos años, la banda de THz sólo había sido explotada para aplicaciones en los campos de la espectroscopía y la radioastronomía. Los avances tecnológicos en la electrónica de microondas y la óptica lastraron el desarrollo de la banda de THz. Sin embargo, investigaciones recientes han demostrado las ventajas asociadas a operar en estas longitudes de onda, lo que ha aumentado el interés y los esfuerzos dedicados a la tecnología de THz. A pesar de que han surgido un gran número de aplicaciones, una de las más prometedoras está en el campo de la vigilancia y la seguridad. Esta tesis está dedicada al desarrollo de radares de onda continua y frecuencia modulada (CW-LFM) de alta resolución en la banda de milimétricas, más concretamente, en las ventanas de atenuación situadas en 100 y 300 GHz. Trabajar en estas bandas de frecuencia presenta beneficios tales como la capacidad de las ondas de atravesar ciertos materiales como la ropa o el papel, opacos en el rango visible, y la posibilidad de usar grandes anchos de banda, obteniéndose así elevadas resoluciones en distancia. Los anchos de banda de 9 y 27 GHz seleccionados para los sistemas de 100 y 300 GHz, respectivamente, proporcionan resoluciones en distancia alrededor y por debajo del cm. Por otro lado, las aplicaciones objetivo se centran en la adquisición de imágenes a corto alcance. En el caso del prototipo a 300 GHz, su diseño se ha orientado a aplicaciones de detección a distancia en escenarios de vigilancia y seguridad. La naturaleza no ionizante de esta radiación supone una ventaja frente a las alternativas tradicionalmente usadas tales como los sistemas de rayos X. La presente tesis se centra en el proceso de diseño, implementación y caracterización de ambos sistemas así como de la validación de su funcionamiento. Se ha elegido una solución basada en componentes electrónicos, y no ópticos, debido a su alta fiabilidad, volumen reducido y amplia disponibilidad de componentes comerciales. Durante el proceso de diseño e implementación, se han tenido en cuenta varias directrices tales como la minimización del coste y la versatilidad de los sistemas desarrollados para hacer posible su aplicación para múltiples propósitos. Ambos sistemas se han utilizado en diferentes pruebas experimentales, obteniendo resultados satisfactorios. Aunque son sólo ejemplos dentro del amplio rango de posibles aplicaciones, la adquisición de imágenes ISAR de modelos de blancos a escala para detección automática así como la obtención de datos micro-Range/micro- Doppler para el análisis de patrones humanos han validado el funcionamiento del sistema a 100 GHz. Por otro lado, varios ejemplos de imágenes 3D obtenidas a 300 GHz han demostrado las capacidades del sistema para su uso en tareas de seguridad y detección a distancia. ABSTRACT The millimeter- and submillimeter-wave bands are the regions of the spectrum between the microwaves and the infrared (IR). The millimeter-wave band covers the range of the spectrum from 30 to 300 GHz, which is usually considered as the extremely high frequency (EHF) band. The range of frequencies between 300 and 3000 GHz is known as the submillimeter-wave or terahertz (THz) band. Nevertheless, the boundaries of the THz band are not accepted by the whole research community. In fact, 100 GHz and 10 THz are often considered by some authors as the lower and upper limit of this band, respectively. Until recently, the THz band had not been exploited for practical applications, with the exception of minor uses in the fields of spectroscopy and radio astronomy. The advancements on microwave electronics and optical technology left the well-known THz gap undeveloped. However, recent research has unveiled the advantages of working at these frequencies, which has motivated the increase in research effort devoted to THz technology. Even though the range of upcoming applications is wide, the most promising ones are in the field of security and surveillance. Particularly, this Ph.D. thesis deals with the development of high resolution continuouswave linear-frequency modulated (CW-LFM) radars in the millimeter-wave band, namely, in the attenuation windows located at 100 and 300 GHz. Working at these wavelengths presents several benefits such as the ability of radiation to penetrate certain materials, visibly opaque, and the great availability of bandwidth at these frequencies, which leads to high range resolution. The selected bandwidths of 9 and 27 GHz for these systems at 100 and 300 GHz, respectively, result in cm and sub-cm range resolution. On the other hand, the intended applications are in the field of short-range imaging. In particular, the design of the 300-GHz prototype is oriented to standoff detection for security and surveillance scenarios. The non-ionizing nature of this radiation allows safety concerns to be alleviated, in clear contrast to other traditional alternatives such as X-rays systems. This thesis is focused on the design, implementation and characterization process of both systems as well as the experimental assessment of their performances. An electronic approach has been selected instead of an optical solution so as to take advantage of its high reliability, reduced volume and the availability of commercial components. Through the whole design and implementation process, several guidelines such as low cost and hardware versatility have been also kept in mind. Taking advantage of that versatility, different applications can be carried out with the same hardware concept. Both radar systems have been used in several experimental trials with satisfactory results. Despite being mere examples within the wide range of fields of application, ISAR imaging of scaled model targets for automatic target recognition and micro-Range/micro-Doppler analysis of human patterns have validated the system performance at 100 GHz. In addition, 3D imaging examples at 300 GHz demonstrate the radar system’s capabilities for standoff detection and security tasks

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols